title: Advanced oxidation protein products and ischaemia-modified albumin in obstructive sleep apnea.
abstract: BACKGROUND
  Several studies have shown that obstructive sleep apnea increases incidence of cardiovascular morbidity and mortality. The high systemic oxidative stress in obstructive sleep apnea has been considered as a major pathogenic mechanism leading to cardiovascular disease. Oxidative stress-related lipid and DNA oxidation in obstructive sleep apnea have been reported in the previous studies. In contrast, there is limited and contradictory information regarding protein oxidation in obstructive sleep apnea patients such as ischaemia-modified albumin and advanced oxidation protein products. Therefore, we aimed to investigate plasma ischaemia-modified albumin and advanced oxidation protein products and their correlation with total oxidative status and total antioxidative capacity in the obstructive sleep apnea patients.
  
  
  METHODS
  Plasma ischaemia-modified albumin, advanced oxidation protein products, total oxidative status and total antioxidative capacity were measured in 25 healthy volunteers and 59 obstructive sleep apnea patients diagnosed with polysomnography.
  
  
  RESULTS
  Plasma total antioxidative capacity was significantly lower (P = 0·012) and total oxidative status was significantly higher (P < 0·001) in the patients compared to the controls demonstrating increased oxidative stress in the patients. Plasma advanced oxidation protein products were significantly higher in the patients than the controls (P = 0·024). Plasma ischaemia-modified albumin levels were not statistically different between the obstructive sleep apnea patients and controls (P = 0·74).
  
  
  CONCLUSIONS
  We conclude that high systemic oxidative stress in obstructive sleep apnea is reflected by increased advanced oxidation protein products without causing an increase in ischaemia-modified albumin.
authors.affiliation: Department of Neurology, Bakirkoy Training and Research Hospital for Psychiatry, Neurology and Neurosurgery Diseases, Istanbul, Turkey.
authors.forename: Serkan
authors.initials: S
authors.lastname: Ozben
authors.forename: Nergiz
authors.initials: N
authors.lastname: Huseyinoglu
authors.forename: Ferhat
authors.initials: F
authors.lastname: Hanikoglu
authors.forename: Tolga Sinan
authors.initials: TS
authors.lastname: Guvenc
authors.forename: Binnaz Zeynep
authors.initials: BZ
authors.lastname: Yildirim
authors.forename: Aysegul
authors.initials: A
authors.lastname: Cort
authors.forename: Sebahat
authors.initials: S
authors.lastname: Ozdem
authors.forename: Tomris
authors.initials: T
authors.lastname: Ozben
mesh_terms: D000328:Adult; D062107:Advanced Oxidation Protein Products / Q000378:metabolism*; D000368:Aged; D015415:Biomarkers / Q000378:metabolism; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000502:physiology*; D012709:Serum Albumin / Q000378:metabolism*; D000075462:Serum Albumin, Human; D020181:Sleep Apnea, Obstructive / Q000378:metabolism*
chemical_list: D062107:Advanced Oxidation Protein Products; D015415:Biomarkers; D012709:Serum Albumin; C561522:ischemia-modified albumin; D000075462:Serum Albumin, Human
keywords: Advanced oxidation protein products; ischaemia-modified albumin; obstructive sleep apnea; oxidative stress; total antioxidative capacity; total oxidative status